DEXIBUPROFEN IS THE DEXTROROTATORY (S(+)), ACTIVE ENANTIOMER OF RACEMIC IBUPROFEN. RACEMIC IBUPROFEN CONSISTS OF EQUAL PORTIONS OF S(+)-IBUPROFEN AND R(-)-IBUPROFEN. POTENTIAL ADVANTAGES OF DEXIBUPROFEN OVER RACEMIC IBUPROFEN INCLUDE LESSER TOXICITY, GREATER CLINICAL EFFICACY AND/OR LESS VARIABILITY IN THERAPEUTIC EFFECTS ACHIEVED